Introduction Despite remarkable therapeutic advances over the last two decades, which
have resulted in dramatic improvements in patient survival, multiple myeloma (MM) is still …

Abstract Purpose of Review We review the recent practice-changing trials of anti-CD19
chimeric antigen receptor (CAR) T cell therapies in large B cell lymphoma (LBCL) including …

Potential synergism between Bruton's tyrosine kinase (BTK) inhibitor and lenalidomide in
treating aggressive B-cell lymphoma has been suggested. Here, the authors report a single …

Abstract Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell
therapy, received the US Food and Drug Administration approval in 2022 for second-line …

T cells modified to express intelligently designed chimeric antigen receptors (CARs) are
exceptionally powerful therapeutic agents for relapsed and refractory blood cancers and …

Personalized therapy offers tailored treatment solutions for individual patients to minimize
treatment-associated side effects and improve prognosis. In particular, endogenous cells …

Adoptive cell therapy with tumor-infiltrating T cells (TILs) has generated exciting clinical trial
results for the treatment of unresectable solid tumors. However, solid tumors remain difficult …

Chimeric antigen receptor (CAR) T–adoptive cell therapy has transformed the treatment of
human hematologic malignancies. However, its application for the treatment of solid tumors …

Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor (CAR)–
modified T-cell therapy administration are either restricted to CARs with 41BB costimulatory …

Engineering a patient's own T cells to accurately identify and eliminate cancer cells has
effectively cured individuals afflicted with previously incurable hematologic cancers. These …